Shares of Histogenics Corp. (NASDAQ:HSGX) were up 4.1% on Wednesday . The company traded as high as $2.39 and last traded at $2.05, with a volume of 94,522 shares. The stock had previously closed at $1.97.

A number of analysts have recently weighed in on HSGX shares. BTIG Research restated a “hold” rating on shares of Histogenics Corp. in a research note on Sunday, May 15th. Canaccord Genuity restated a “buy” rating on shares of Histogenics Corp. in a research note on Thursday, May 12th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $12.13.

The company’s 50-day moving average is $1.85 and its 200-day moving average is $2.24. The company’s market capitalization is $26.54 million.

Histogenics Corp. (NASDAQ:HSGX) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.01. During the same period in the prior year, the company earned ($0.60) EPS. On average, equities analysts predict that Histogenics Corp. will post ($2.15) earnings per share for the current year.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.